Advanced Solid Tumor Clinical Trials

122 studies are recruiting for advanced solid tumor in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 4

1. A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

   This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study nea…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Colorado Cancer Center, Aurora, Colorado

   Locations

   5 in total

   Run by

   7 Hills Pharma, LLC

   See if you can join NCT06362369 on ClinicalTrials.gov

2. An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

   The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Prisma Health-Upstate, Greenville, South Carolina

   Locations

   7 in total

   Run by

   FBD Biologics Limited

   See if you can join NCT06487624 on ClinicalTrials.gov

3. A Study of DB-1310 in Advanced/Metastatic Solid Tumors

   This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, Davis Comprehensive Cancer Center, Sacramento, California

   Locations

   24 in total

   Run by

   DualityBio Inc.

   See if you can join NCT05785741 on ClinicalTrials.gov

4. 64Cu-GRIP B in Patients With Advanced Malignancies

   This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patie…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Rahul Aggarwal

   See if you can join NCT05888532 on ClinicalTrials.gov

5. Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

   This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   National Cancer Institute, Bethesda, Maryland

   Locations

   5 in total

   Run by

   Ankyra Therapeutics, Inc

   See if you can join NCT06171750 on ClinicalTrials.gov

6. Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions

   The purpose of this study is to determine whether a consultation with a Personalized Therapeutics Clinic, or PTC, will help participants lower the risk for side effects (drug-drug interactions and drug-gene interactions) when taking many medications and help providers improve prescribing decisions …

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Chicago Medicine, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT05166694 on ClinicalTrials.gov

7. STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study

   This is a non-randomized two-arm trial, specifically a pilot study in which patients with advanced solid tumor cancer with 3-10 metastatic lesions who are on immunotherapy will receive ablative RT to up to 10 lesions. After study intervention, participants will undergo ctDNA collection at 8 weeks a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Illinois at Chicago, Chicago, Illinois

   Run by

   University of Illinois at Chicago

   See if you can join NCT07269080 on ClinicalTrials.gov

8. First in Human Study of TORL-1-23 in Participants With Advanced Cancer

   This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Providence Medical Foundation, Fullerton, California

   Locations

   14 in total

   Run by

   TORL Biotherapeutics, LLC

   See if you can join NCT05103683 on ClinicalTrials.gov

9. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

   Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   21 in total

   Run by

   Clasp Therapeutics, Inc.

   See if you can join NCT06778863 on ClinicalTrials.gov

10. A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

    The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hematology-Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida

    Locations

    8 in total

    Run by

    FBD Biologics Limited

    See if you can join NCT05892718 on ClinicalTrials.gov

11. Evaluate the Safety and Clinical Activity of HH2853

    This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui

    Locations

    25 in total

    Run by

    Haihe Biopharma Co., Ltd.

    See if you can join NCT04390737 on ClinicalTrials.gov

12. A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

    This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose …

    Stage

    Not phased

    Ages

    18 and older

    Site

    UC San Diego Moores Cancer Center, La Jolla, California

    Locations

    2 in total

    Run by

    Replimune, Inc.

    See if you can join NCT06887348 on ClinicalTrials.gov

13. A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

    This is a 3-part study. Phase 1a (dose escalation) is designed to assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and putative recommended phase 2 dose (RP2D) of study drug as monotherapy. Phase 1b (Cohort Expansion) is intended to further characterize the safet…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Scripps Green Hospital, La Jolla, California

    Locations

    6 in total

    Run by

    OBI Pharma, Inc

    See if you can join NCT07124117 on ClinicalTrials.gov

14. A Study of YL242 in Subjects With Advanced Solid Tumors

    This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    US-202, Sarasota, Florida

    Locations

    15 in total

    Run by

    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT07197827 on ClinicalTrials.gov

15. JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

    This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    California Cancer Associates for Research and Excellence, Encinitas, California

    Locations

    10 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT06108050 on ClinicalTrials.gov

16. FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

    This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    14 in total

    Run by

    Fate Therapeutics

    See if you can join NCT06241456 on ClinicalTrials.gov

17. Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

    Open-label, two parallel arm, multicenter, Phase 1 dose-escalation study to evaluate the safety and tolerability of OMTX705, both as monotherapy or in combination with pembrolizumab (Part 1) or tislelizumab (Part 2) in the treatment of patients with advanced or metastatic cancer in whom there is no…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Locations

    9 in total

    Run by

    Oncomatryx Biopharma S.L.

    See if you can join NCT05547321 on ClinicalTrials.gov

18. Study of AVZO-021 in Patients With Advanced Solid Tumors

    This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale Cancer Center, New Haven, Connecticut

    Locations

    13 in total

    Run by

    Avenzo Therapeutics, Inc.

    See if you can join NCT05867251 on ClinicalTrials.gov

19. First in Human, Dose Escalation Study of AN4005

    Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of AN4005. Except for Dose Level 0 (50 mg), a traditional "3 +…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hackensack University Medical Center, Hackensack, New Jersey

    Locations

    7 in total

    Run by

    Adlai Nortye Biopharma Co., Ltd.

    See if you can join NCT04999384 on ClinicalTrials.gov

20. Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

    This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas

    Locations

    2 in total

    Run by

    Aadi Bioscience, Inc.

    See if you can join NCT05661461 on ClinicalTrials.gov

21. A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

    This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Southern California, Los Angeles, California

    Locations

    14 in total

    Run by

    Volastra Therapeutics, Inc.

    See if you can join NCT05902988 on ClinicalTrials.gov

22. Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

    Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study no…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NextGen Oncology, Beverly Hills, California

    Locations

    7 in total

    Run by

    Strand Therapeutics Inc.

    See if you can join NCT06249048 on ClinicalTrials.gov

23. Clinical Trial of PM54 in Advanced Solid Tumors Patients.

    The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - safety run-in and expansion) will be to reassess the maximum tolerated dose (MTD) defined in the Phas…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    South Texas Accelerated Research Therapeutics, San Antonio, Texas

    Locations

    3 in total

    Run by

    PharmaMar

    See if you can join NCT05841563 on ClinicalTrials.gov

24. A Study of LM-24C5 For Advanced Solid Tumors

    To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Ocala Oncology, Ocala, Florida

    Locations

    6 in total

    Run by

    LaNova Medicines Limited

    See if you can join NCT06187402 on ClinicalTrials.gov

25. A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

    This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Exelixis Clinical Site #15, Jacksonville, Florida

    Locations

    16 in total

    Run by

    Exelixis

    See if you can join NCT05932862 on ClinicalTrials.gov